Skip to main content

Table 2 Best overall responses

From: Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

  Number Percent
PB regimen (n = 51)
 CR 0 0.0
 PR 26 51.0
 SD 20 39.2
 PD 5 9.8
 NE 0 0.0
 ORR (CR + PR) 26 51.0
 95% CI 36.6–65.3  
 DCR (CR + PR + SD) 46 90.2
 95% CI 78.6–96.7  
Maintenance treatment with eribulin (n = 45)
 CR 0 0.0
 PR 29 64.4
 SD 13 28.9
 PD 3 6.7
 ORR (CR + PR) 29 64.4
 95% CI 48.8–78.1  
 DCR (CR + PR + SD) 42 93.3
 95% CI 81.7–98.6  
  1. BP bevacizumab + paclitaxel, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate, CI confidence interval